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ABSTRACT 
BACKGROUND AND OBJECTIVE: The expression of some circulating microRNAs (miRNAs) in biological fluids 
of healthy individuals is different from cancerous patients. circulating miRNAs are a new class of cancer biomarkers 
because of their high stability and sensitivity, ease of measurement and specificity due to their correlation with various 
cancer states. According to the miR-451 and miR-21 functions in the metastasis of some cancers, the aim of this study 
was to investigate the differences of expression levels of miR-451 and miR-21 in the plasma of breast cancer (BC) 
patients with and without lymph nodes metastasis (LNM). 
METHODS: In this descriptive-analytical study, blood samples were collected from 47 women with BC and 24 
healthy women with mammography confirmation. The presence/or absence of LNM was recognized from patients' 
medical records. The expression levels of miR-451 and miR-21 in the plasma, were investigated using Real-Time PCR. 
FINDINGS: The median of expression of miR-451 in BC patients with LNM and without LNM was 1.739 and 3.187, 
respectively, and its expression in lymph node metastatic patients decreased 0.444 folds in comparison with non-
metastatic patients (p=0.031). The median of expression of miR-21 in patients with LNM and in non-metastatic lymph 
nodes patients was 5.922 and 2.157, respectively, and its expression in metastatic status was 2 folds higher than non-
metastatic (p=0.029). 
CONCLUSION: The results of this study indicated that decreased miR-451 and increased miR-21 expression in 
plasma of BC patients was associated with LNM status. 
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Introduction 
Breast cancer is the most common type of cancer 
in women. Recurrence and metastasis are the main 
causes of death from this cancer (1). The status of 
metastasis to lymph nodes is one of the most important 
prognostic factors in breast cancer and it is important 
in clinical decision-making, proper surgical selection 
and treatment outcomes (2). This parameter is a 
measure of the survival status of patients (3). Most 
conventional diagnostic methods and biomarkers in 
breast cancer are not able to detect metastatic lymph 
nodes, and accepted methods such as lymphatic 
mapping and biopsy of lymph nodes can not be applied 
to all patients (4). 
Therefore, the identification of noninvasive 
biomarkers is important for tracking lymph node 
metastases. miRNAs are a type of non-coding RNAs. 
Exposure profiles of microRNAs have high potential 
for specific detection of different cancers, as well as 
pathologic stages and pathologies different from one 
type of cancer (5). In breast cancer, miR-451 and miR-
21 expressions are disregulated in tumor cells and 
some biological fluids such as plasma (7, 6). In many 
studies, the role of miR-21 as a key onco miR has been 
identified that increasing the expression of miR-21 in 
tumor tissue is associated with the onset, progression 
or metastasis of some cancers (8, 1).  
On the other hand, miR-451 is a tumor suppressant. 
Consequently, the reduction of the expression of this 
miRNA plays a role in breast cancer (9). Considering 
the importance of the status of lymph node metastases 
for better managment of breast cancer in order to use 
the appropriate treatment protocol (2) and considering 
the role of miR-451 and miR-21 in metastasis (9), in 
the present study for the first time non-invasive 
analysis of the possible changes in the level of 
expression of these two miRNAs in the blood plasma 
of patients with breast cancer in relation to the status of 
metastatic lymph nodes compared to healthy subjects. 
By continuing this study in the future, it might be 
possible to use two miRNAs as noninvasive 
biomarkers to detect breast cancer metastasis to lymph 
nodes. 
 
 
Methods 
In this descriptive-analytical study, after approval 
by the ethics committee of Shahrekord University of 
Medical Sciences (Registration code: 
IR.SKUMS.REC.1394.178), peripheral blood of 47 
women with breast cancer and 24 healthy women were 
collected. Women with all four stages of breast cancer 
and ductal carcinoma were included in the study. 
Healthy people were selected with a mean age similar 
to women with breast canser who had been 
mammographed during the sampling period and their 
health was confirmed. Confirmation of the health or 
illness of the women studied by examining or 
considering a mammogram report by an oncologist 
(10). Samples were collected from Isfahan and Shahr-
e-Kord Hospitals, after obtaining written consent and 
during 18 months, from 2015 to 2016. 
Clinical information such as the stage of cancer, the 
presence or absence of metastasis to the lymph nodes 
after surgery, and the sending of mass samples to the 
laboratory were determined by the pathologist. Blood 
plasma was isolated from other parts by blood 
centrifuge in 7 minutes and with 2500 rpm. The 
expression of miR-451 and miR-21 variables in two 
groups of breast cancer patients (eligible/without 
metastasis of lymph nodes) were evaluated using Real-
Time PCR.  
From 250 μl of plasma samples, miRNAs were 
extracted using a kit (exiqon, 300112). Subsequently, 
cDNA synthesis was performed using kits (00101005, 
Pars Genome) and based on the company protocol. 
Real-Time PCR reaction was performed using 
SYBRGreen (RRS20Q, Takara) and miR-451, miR-21 
specific primers and internal control gene U6snRNA 
(00101007, Pars Genome).  
The Real-Time PCR reaction was performed with 
three repetitions for each sample. Expression ratios for 
miR-21 and miR-451 in plasma of patients were 
calculated by the ΔΔCt-2 formula in ΔCt = 
Ctinterested miRNA - CtU6snRNA and ΔΔCt = 
ΔCtsample (patient) - ΔCtcontrol. Data analysis was 
performed using SPSS software version 18 (SPSS Inc., 
Chicago, Ill., USA) and the analysis of variance and 
Fisher's exact test were used for comparison between 
the two groups and the non-parametric Mann-Whitney 
U test was used for comparison of expression changes 
and p<0.05 was considered significant. 
 
 
Results 
Variables: Clinopathological profile: The mean age of 
healthy and ill women were 45.6±14.3 and 49.6±10 
years, respectively. Out of 47 women with breast 
cancer, 29 had metastasis to lymph nodes (Table 1). 
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metastasis of lymph nodes: The mean ratio of 
expression of miR-451 in breast cancer patients with 
lymph node metastases and no lymph node metastasis 
was 1.73 and 3.871, respectively. Therefore, the 
expression of miR-451 in the plasma of metastatic 
patients decreased by 0.444 (p=0.031) compared to 
non-metastatic patients (Fig.1A). The association of 
miR-451 expression in plasma with other clinical 
features: changes in the expression of miR-451 in 
relation to the status of ER, PR, Her2 and the stage of 
breast cancer were not significant (p=0.682, p=0.973, 
p=0.823 and p=0.344). The association of miR-21 
expression in plasma with metastasis in the lymph 
nodes: The mean ratio of miR-21 expression in 
patients with metastatic lymph nodes and in patients 
without metastasis were 5.92 and 5.157, respectively. 
The expression of miR-21 in metastatic state was 2 
times higher than non-metastasis (p=0.029) (Fig. 1B). 
 
Table 1. Clinopathological profile of patients: The number of each patient is shown in  
terms of the variables studied 
Number of patients Level of variable Variable 
2 one 
Stage 
17 Two 
4 three 
3 four 
18 positive 
ER Receptor  
5 negative 
16 positive 
PR Receptor  
7 negative 
5 positive 
Her2/nu Receptor 
18 negative 
29 positive 
Lymph node metastases 
18 negative 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. MiR-451 and miR-21 expression patterns associated with metastasis of lymph nodes in breast cancer: 
(a) related to changes in the expression of miR-451; and (b) miR-21 expression changes. The level of expression 
of these two microRNAs in comparison with the absence of metastasis was decraesed 0.442 fold (p = 0.031) and 
increased 2 times, respectively (p=0.029). 
 
Discussion 
In this study, changes in plasma miR-451 and miR-
21 plasma expression in patients with breast cancer, 
with regard to the status of metastasis to lymph nodes, 
were significantly altered in these patients. 
Identification of lymph node metastases plays a very 
important role in the treatment of breast cancer and 
plays a role in the choice of surgical procedure and 
subsequent therapeutic treatment (4). Previous studies 
have shown that miR-451 plays a role in tumor 
suppression in various cancers. Pan et al. showed that 
most of the target genes of the miRNA, such as c-Myc, 
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RAB14 and others, are oncogene and play a role in 
tumorogenesis and metastatic pathways. Obviously, 
the results of many studies on various cancers indicate 
a reduction in the expression of miR-451 in tumor cells 
(11). The results showed that the plasma expression of 
miR-451 is reduced in relation to breast cancer 
metastasis. Bandres et al showed that a lower 
expression of miR-451 is associated with a lower 
survival of gastric cancer patients (12).  
Another study by Wang et al. on lung cancer 
revealed a reduction in the expression of miR-451 with 
more advanced stages, metastasis to lymph nodes, and 
tumor differentiation (13). Plasma miR-21 plasma 
concentrations were higher in patients with metastatic 
lymph nodes than in patients without lymph node 
metastasis. This finding is also consistent with some 
similar studies in this area. Yan and colleagues 
compared the breast tumor tissue with healthy 
surrounding tissues and it was found that increased and 
elevated expression of miR-21 was associated with 
more advanced stages of cancer and metastases to 
lymph nodes (14). 
In a study by Ota et al. on bone marrow tissue in 
breast cancer patients, individuals with metastatic 
lymph nodes had a higher expression of miR-21 than 
non-metastatic patients (15). Due to the higher value of 
noninvasive studies than biopsy, in the present study, 
the use of plasma versus tissue samples has been used 
in previous studies. The results suggest that expression 
of miR-21 increases when disease progresses, and 
especially during metastases. Melnik et al showed that 
miR-21 is a key onco miR, and in many cancers, the 
level of its expression is elevated. Maintaining the 
prolifration signal, escape from growth inhibitors, 
activating invasion and metastasis, inducing 
angiogenesis and oxidative stress, as well as genetic 
instability are some of  its roles (16). Zhu et al. showed 
that PDCD4 (programmed cell death protein) and 
Maspin are miR-21 targets that reduce the potential for 
invasion and metastasis in breast cancer. Thus, miR-21 
is important for tumor cell invasion by targeting 
metastasis inhibitors (17). In general, these studies can 
explain the link between increased expression of miR-
21 and a greater reduction in the expression of miR-
451 in parallel with the presence of metastasis to 
lymph nodes. It can be concluded that with significant 
changes in the level of expression of miR-451 and 
miR-21 in relation to metastasis of lymph nodes in 
breast cancer patients, and on the other hand, due to 
changes in expression in plasma of patients that 
compared with tissue samples in the previous studies is 
less invasive, so it may be possible to use these two 
miRs in determining the prognosis of the metastasis 
and, consequently, the determination of therapeutic 
approaches. 
Suggestions: In order to confirm the correlation 
between the clinical features of breast cancer with 
changes in the expression of miR-451 and miR-21 in 
the plasma of patients and their use as prognostic 
biomarkers in breast cancer, it is suggested a study 
with more sample size in this regard. 
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